# Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

> **NCT00346073** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 2337 (actual)

## Conditions studied

- Acellular Pertussis
- Diphtheria
- Tetanus

## Interventions

- **BIOLOGICAL:** Boostrix™
- **BIOLOGICAL:** ADACEL®

## Key facts

- **NCT ID:** NCT00346073
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07-13
- **Primary completion:** 2007-03-01
- **Final completion:** 2007-03-07
- **Target enrollment:** 2337 (ACTUAL)
- **Last updated:** 2018-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00346073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00346073, "Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT00346073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*